StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reissued an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

NYSE:NSPR opened at $2.92 on Tuesday. The stock has a market capitalization of $76.15 million, a P/E ratio of -3.63 and a beta of 0.93. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42. The company has a 50 day moving average price of $2.58 and a 200 day moving average price of $2.63.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the previous year, the firm posted ($0.15) earnings per share. Research analysts forecast that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

Hedge funds have recently modified their holdings of the stock. Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD during the third quarter worth approximately $279,000. Affiance Financial LLC acquired a new position in InspireMD during the 3rd quarter worth approximately $492,000. Finally, Rosalind Advisors Inc. increased its position in shares of InspireMD by 266.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after purchasing an additional 1,827,579 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.